Precision Diagnostics

• The FDA-cleared AXINON^® LDL-p Test System, is a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.

• Currently, Numares is the only company in the US selling an FDA-cleared NMR test.

• A second Numares assay is expected to gain FDA 510(k) clearance later this year, the AXINON^® GFR(NMR) kidney function assay.

• The AXINON^® HCC(NMR), a liver assessment and cancer early detection test, is in development. 

Cardiology

AXINON^® LDL-p Test System: Now FDA-cleared, provides more detailed information about cardiac function than the standard LDL-C (low-density lipoprotein or “bad cholesterol”) measurement.

AXINON^® lipoFIT^®: For cardiovascular risk assessment. Available as a CE-labeled IVD in the EU. For research use only in the US.

Nephrology

AXINON^® GFR(NMR): New kidney function assay that combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy. FDA 510(k) pending and available as a CE-labeled IVD in the EU.

Hepatology

AXINON^® HCC(NMR): Liver risk assessment and cancer early detection test. In development.